Alnylam will likely face challenges in turning a profit this year, despite executives promising to do so. But the label for its newly-approved Amvuttra indication …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
A new study indicates that severity of amyloid deposition in the brain -; not just age -; may be key to determining who will benefit
EQS Newswire / 27/05/2024 / 22:00 UTC+8 TOT Biopharm (1875.HK) has reached a new milestone in its performance. On May 10th, the company announced its 24Q1 financial
Developing effective treatments and understanding how the mechanism of the immune system have always been challenging for scientists. T cells, which are the frontline warriors